Peripheral Blood Cell Ratios as Prognostic Indicators in a Neoadjuvant Chemotherapy-Treated Breast Cancer Cohort Amirhossein Jalali and James A. L. Brown

Our multidisciplinary study investigated how we can actively use commonly collected information, found in the blood of breast cancer patients treated with neoadjuvant chemotherapy, to provide clinicians with a new prognostic aid for the management of breast cancer. We found that comparing numbers of key blood-based cell types (giving us immunocyte ratios) allowed us to predict overall survival and disease-free survival of patients in some key breast cancer subtypes.

Clinically, calculating these ratios is a simple and quick use of existing data, and provides another useful way for clinicians to predict how some breast cancer patients will respond to treatment, improving their disease management.